Table 5.

Summary of median overall survival (OS) and progression-free survival (PFS) between dacomitinib and placebo according to previous response to EGFR TKIs in NCIC-BR-26

Best response to EGFR TKIs	Dacomitinib		Placebo		HR	95% CI	Interaction P-value
	Median	95% CI	Median	95% CI
Median OS (months)
Progressive disease	5.49	4.73–6.28	7.52	5.16–9.13	1.36	1.00–1.87
Others	7.56	6.77–8.28	6.01	5.13–7.33	0.79	0.65–0.97	0.003
Median PFS (months)
Progressive disease	1.71	1.12–1.84	1.74	0.92–2.04	1.05	0.78–1.41
Others	3.52	2.83–3.61	1.12	0.95–1.71	0.56	0.46–0.68	0.001

Note: “Others” included complete/partial response, stable disease, and unknown. Data from Ellis et al.28

Abbreviations: CI, confidence interval; TKIs, tyrosine-kinase inhibitors; HR, hazard ratio.